SCHEMBL1428063

SCHEMBL1428063

CN(C)CCNC(=O)c1nc(Cl)c(N)nc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
SCNN1A P37088 7/20 0.46
GRM5 P41594 1/20 0.43
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 5/20 0.42
HPGD P15428 5/20 0.42
HSD17B10 Q99714 5/20 0.42
GLA P06280 4/20 0.42
CYP1A2 P05177 4/20 0.42
GAA P10253 3/20 0.42
CYP2D6 P10635 3/20 0.42
LMNA P02545 3/20 0.42
FTO Q9C0B1 2/20 0.42
BLM P54132 2/20 0.42
SLC22A1 O15245 1/20 0.42
PLAU P00749 1/20 0.42
HTR1A P08908 1/20 0.42
TSHR P16473 1/20 0.42
SLC9A1 P19634 1/20 0.42
MAOA P21397 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7293251 0.86 SCNN1A (0.42) MAPK1SCNN1AGRM5ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL10334226 0.85 SCNN1A (0.41) MAPK1SCNN1AGRM5ALDH1A1KDM4E
SCHEMBL16541800 0.83 SCNN1A (0.53) SCNN1AGRM5ALDH1A1KDM4EHPGD
SCHEMBL2287885 0.83 SCNN1A (0.41) SCNN1AGRM5ALDH1A1KDM4EHPGD
SCHEMBL10461270 0.83 SCNN1A (0.43) SCNN1AGRM5ALDH1A1KDM4EHPGD
SCHEMBL10462647 0.82 MEN1 (0.44) SCNN1AGRM5ALDH1A1KDM4EHPGD
SCHEMBL1441745 0.82 SCNN1A (0.48) SCNN1AGRM5ALDH1A1KDM4EHPGD
SCHEMBL1429031 0.81 SCNN1A (0.50) MAPK1SCNN1AGRM5ALDH1A1KDM4E
SCHEMBL1428384 0.81 SCNN1A (0.39) SCNN1AGRM5ALDH1A1KDM4EHPGD
SCHEMBL10461276 0.81 SCNN1A (0.41) SCNN1AGRM5ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201625-A1 Organic Comopunds NOVARTIS AG (CH) 2011-08-18 US disclosed
EP-2300010-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2011-03-30 EP disclosed
WO-2011028740-A1 ENaC BLOCKERS GLAXO GROUP LIMITED (GB) 2011-03-10 WO disclosed
WO-2011028740-A1 ENaC BLOCKERS GLAXO GROUP LIMITED (GB) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201625-A1 Organic Comopunds OR10J3, CFTR, CLIC1 MAPK1 3731/4885SCNN1A 52/4885GRM5 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.